July 3, 2019
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based B...
July 1, 2019
Bukwang’s successful launch of Neomed toothpaste on home-shopping marked its expansion on OTC business.
June 28, 2019
BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture
The first global investment by BNO BIO since...
June 26, 2019
- to be completed within 2 years
Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM...
December 17, 2018
- Fast speed of study progression, expecting results in January next year
MLR-1023’s phase 2b study is completed on Decem...
November 29, 2018
Bukwang announced that it has completed the clinical trials of MLR-1023, a new diabetic drug candidate. This is a phase...
October 22, 2018
Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candi...
August 14, 2018
On August 14, 2018, the two companies signed a contract to transfer all rights of Rivoceranib held by Bukwang Pharmaceut...
August 7, 2018
- 400 patient enrollment in 61 sites (US & KR)
Bukwang Pharmaceutical Co., Ltd. announced completion of global Phase 2b s...
July 4, 2018
More than 360 patients dosed out of 400 patients in the US and Korea
MLR-1023, a new anti-diabetic drug from Bukwang Phar...
< Newer Posts
Older Posts >
Bukwang’s antiviral drug, Levovir®, confirms antiviral effect against coronavirus
March 10, 2020
Bukwang receives US FDA approval for JM-010 phase 2 clinical study IND
February 14, 2020
Bukwang Initiates Exportation of its
In-House-Developed Drug, DEXIDⓇ to Southeast Asia
January 31, 2020
Bukwang initiates dosing of JM-010 in Europe phase 2 study
January 10, 2020
Bukwang Pharmaceutical has entered into co-promotion agreement with Sanofi- Aventis Korea on AprovelⓇ product family
January 2, 2020
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
November 13, 2019
ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
September 30, 2019
Bukwang Pharmaceutical hosted a keynote lecture by a renowned expert in pulmonary allergy
July 25, 2019
Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment
July 10, 2019
Bukwang’s representative ethical products outperformed
July 5, 2019